<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03709056</url>
  </required_header>
  <id_info>
    <org_study_id>HSK3486-203</org_study_id>
    <nct_id>NCT03709056</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Efficacy and Safety of HSK3486</brief_title>
  <official_title>A Phase IIb, Randomized, Double-blind, Propofol-controlled, Multi-center Study Evaluating the Efficacy and Safety of HSK3486 for Sedation and Anesthesia in Patients Undergoing Diagnostic Colonoscopy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sichuan Haisco Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sichuan Haisco Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A double-blind, randomized, active controlled, multi-center, parallel group study comparing
      HSK3486 with Propofol, in patients undergoing a colonoscopy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 14, 2017</start_date>
  <completion_date type="Actual">August 9, 2018</completion_date>
  <primary_completion_date type="Actual">February 2, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Success of colonoscopy procedure</measure>
    <time_frame>from the first dose of the study drug to removal of colonoscope on day 1</time_frame>
    <description>Measured by completion of colonoscopy, no requirement for an alternative sedative or anesthesia drug and no requirement for more than 5 doses of study drug within any 15 minute period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to start of procedure</measure>
    <time_frame>From first dose of study drug until insertion of colonoscope on day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The success rate of the colonoscopy procedure</measure>
    <time_frame>from the first dose of the study drug to removal of colonoscope on day 1</time_frame>
    <description>The number of patients who successfully completed the colonoscopy procedure accounted for the proportion of all patients in the dose group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to fully alert</measure>
    <time_frame>from the removal of colonoscopy procedure, until the first of three consecutive MOAA/S scores of 5 on day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to discharge</measure>
    <time_frame>from the removal of colonoscopy procedure, until the first of three consecutive Aldrete scores of more than or equal to 9 on day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Application of study drug and alternative medication</measure>
    <time_frame>during the colonoscopy procedure on day 1</time_frame>
    <description>total dosages of study drug and alternative medication</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">94</enrollment>
  <condition>Sedation and Anesthesia for Adult Colonoscopy Procedures</condition>
  <arm_group>
    <arm_group_label>HSK3486 0.4/0.2mg/kg ，0.5mg/kg/0.15mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Propofol 2.0/1.0mg/kg group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HSK3486</intervention_name>
    <description>HSK3486 intravenous (iv) 0.4(0.5) mg/kg for induction, and 0.2 (0.15)mg/kg top-ups for maintenance. 0.3(0.375) mg/kg for induction and 0.15 (0.113)mg/kg for maintenance in adults of 65-70 years old</description>
    <arm_group_label>HSK3486 0.4/0.2mg/kg ，0.5mg/kg/0.15mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>Propofol iv 2.0 mg/kg for induction, and 1.0 mg/kg top-ups for maintenance. 1.5 mg/kg for induction and 0.75mg/kg for maintenance in adults of 65-70 years old.</description>
    <arm_group_label>Propofol 2.0/1.0mg/kg group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Scheduled to undergo a diagnostic or therapeutic colonoscopy;

          2. Male or female patients, ASA grade I~III, aged ≥ 18 and≤ 70;

          3. Body mass index (BMI) ≥ 18 and ≤ 30 kg/m2;

          4. the respiratory rate ≥10 and ≤24, SpO2 when inhaling ≥95%, SBP≥90mmHg, DBP≥60mmHg,
             HR≥55and ≤100;

          5. Patient can understand the procedure of this study and is willing to comply with study
             requirements. The patient can sign the ICF voluntarily.

        Exclusion Criteria:

          1. Patients were contraindicated in general anesthesia.

          2. Patients with a known sensitivity to propofol, opioids, naloxone, eggs, soy products
             or a medical condition such that these agents were contraindicated.

          3. The patient has some history or evidence of increased risk of sedation or anesthesia,
             such as cardiovascular disease, respiratory disease, cerebrovascular disease,
             gastrodintestinal disease and other system disease prior to the screening and/or
             baseline period.

          4. Patients with a history of drug or ethanol abuse with the past 3 months.

          5. Patients with respiratory management difficulties.

          6. Patients in receipt of any investigational drug within 30 days before screening.

          7. Patients in receipt of propofol, opioid , other sedative or anesthetic or analgesics
             within 72 hours before screening.

          8. Abnormal laboratory results consisting of any of the following:

        1) neutrophil count≤ 1.5×109/L； 2）platelet≤ 80×109/L； 3）hemoglobin≤ 90 g/L; 4）aspartate
        aminotransferase≥ 1.5×ULN； 5) serum creatinine≥ 1.2×ULN. 9. Pregnant women or female
        patients with a positive serum or urine human chorionic gonadotropin pregnancy test at
        screening or baseline or lactating female patients.

        10. Patients with an inability to communicate well with the investigator, or deemed
        unsuitable according to the investigator (in each case providing a reason)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University</name>
      <address>
        <city>Changde</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Third Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sichuan Provincial People's Hospital</name>
      <address>
        <city>Chengdu</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Fengxian District Central Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The second Affiliated Hospital of Wenzhou Medical University</name>
      <address>
        <city>Wenzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Union Hospital of Tongji Medical College, Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of Ningxia Medical University</name>
      <address>
        <city>Yinchuan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 8, 2018</study_first_submitted>
  <study_first_submitted_qc>October 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 17, 2018</study_first_posted>
  <last_update_submitted>October 16, 2018</last_update_submitted>
  <last_update_submitted_qc>October 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

